ABOUT US
We are a portfolio biopharmaceutical company. We translate breakthroughs in biology and basic medical research into innovative new medicines. With over 20 active therapeutic programs, six of which are in development, we are building a large, diversified portfolio of novel therapeutics with uncorrelated risk. We are located in Cambridge and Oxford, UK, and Boston and Chicago, USA.
We have a scalable R&D platform for the evergreen discovery and development of new medicines. This is enabled by an unprecedented level of access to breakthroughs in biology and basic medical research made at six of the world’s leading universities and research institutes with whom we are partnered.
We also in-license or acquire clinical-stage programs where we have unique insights and synergies arising from our discovery and preclinical activities to further accelerate the growth of our portfolio.
INVESTORS
We are backed by leading specialist investors including Patient Square Capital and Rock Springs Capital.
Meet Apollo
We are a team of highly seasoned drug discoverers, drug developers, and related roles. We typically recruit people at the top of their game inside the world’s major pharma companies, while they still have direct accountability for scientific delivery and strategy. By joining us, leaders can continue to excel and grow at the front line of science, therapeutics R&D, and strategy. We apply the same principles to our non-R&D roles and support functions.
Our portfolio-model is built around a centralized management team of capital allocators and functional leaders with deep expertise in biology and pharmaceutical R&D, manufacturing, commercial strategy, fund-raising and finance, and business development, leveraged over a diverse portfolio of therapeutic programs, each led by a dedicated and seasoned global program leader.
